Publication | Closed Access

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

VaccinationVaccine SafetyCervical Cancer ScreeningPreventive MedicineCervical CancerCervical HealthHuman Papillomavirus VaccinesPrecancerous LesionsHpv-16/18 As04-adjuvanted VaccineVaccine TrialVaccine EfficacyCross-protective EfficacyPublic HealthMedicineDouble-blind Patricia TrialEpidemiologyCervical Cancer Prevention